Strategist: Buy Baxter stock, skip Eli Lilly stock

Novo Nordisk (NVO) was named Yahoo Finance's Company of the Year thanks to the success of its diabetes and weight loss drugs, Ozempic and Wegovy. But there are other ways you can play the GLP-1 hype.

In the latest edition of "Good Buy or Goodbye," Great Hill Capital Chairman and Managing Member Tom Hayes suggests buying Baxter International (BAX). There are a few reasons why Hayes likes the stock including that it has aggressively sold off, the "valuation is tremendous," and that it has potential catalysts for the stock to recover some of its losses.

The stock Hayes is not buying right now is Eli Lilly (LLY). Hayes argues that the stock has already priced in a lot of good news, there will be increased competition, and that there are still questions about what insurance companies will cover when it comes to obesity drugs.

About Yahoo Finance:

Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.

Get the latest news and data at finance.yahoo.com

Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)

Follow Yahoo Finance on social:

X:   / yahoofinance  
Instagram: https://www.instagram.com/yahoofinanc...
TikTok: https://www.tiktok.com/@yahoofinance?...
Facebook:   / yahoofinance  
LinkedIn:   / yahoo-finance  

#baxter #elililly #yahoofinance